Charlotte Moser, MD, PhD, MSc, MBA, Chief Medical Officer (CMO), Deb Kientop as Vice President, Clinical Operations at Deka Biosciences

GERMANTOWN, Md., Sept. 8, 2022 /PRNewswire/ -- Deka Biosciences ("Deka"), a biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases, announced today the appointment of Charlotte Moser, MD, PhD, MSc, MBA as Chief Medical Officer (CMO) and Deb Kientop, MBA as Vice President, Clinical Operations.

Charlotte Moser, MD, PhD, MSc, MBA, Chief Medical Officer (CMO), Deb Kientop as Vice President, Clinical Operations at Deka Biosciences "We are proud to have both Charlotte and Deb joining Deka during this exciting time," said John Mumm, Chief Executive Officer, Deka. "Both come to Deka with strong experience, knowledge and expertise, which will help to deliver life-saving therapies to patients, and drive expansion of our platform, and overall growth of Deka."

Image: Charlotte Moser, MD, PhD, MSc, MBA, Chief Medical Officer (CMO), Deb Kientop as Vice President, Clinical Operations at Deka Biosciences

Nih logo 2101026093

The National Institutes of Health has issued two new funding opportunities for diagnostic test manufacturers to develop the next generation of COVID-19 tests, with a major focus on accessibility. The funding opportunities are part of the Rapid Acceleration of Diagnostics (RADx) Tech program, managed by the National Institute of Biomedical Imaging and Bioengineering (NIBIB). The new programs may award up to $300 million in funds from the American Rescue Plan Act of 2021 to support the accelerated development of tests and provide regulatory guidance during the COVID-19 pandemic and beyond.


Adaptive phage therapeutics

September 07, 2022 08:00 AM Eastern Daylight Time

GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company controlling the world’s largest therapeutic phage library initiative and dedicated to providing therapies to treat infectious diseases, today announced “The AMR RAPID™ Challenge” at the World AMR Congress. RAPID is APT’s acronym for Rapidly Adaptive Phage for Infectious Disease.

Through this challenge, APT will pay $1,000 to any individual or institution in the clinical research community that identifies a strain of bacteria (within the CDC's most serious and urgent biological threat categories -- i.e., the "ESKAPE" pathogens*) for which APT cannot demonstrate sensitivity to with its phage bank. Applicants to the AMR RAPID™ Challenge should contact This email address is being protected from spambots. You need JavaScript enabled to view it. for further information, rules, and conditions or visit

Cursor and Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders Business Wire

Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that have the potential to increase immunotherapy options for patients

September 08, 2022 07:00 AM Eastern Daylight Time

GENEVA & GAITHERSBURG, Md.--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients. Per the agreement, NexImmune will leverage Selexis’ SUREtechnology Platform™, a suite of cell line development technologies that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines.


I'm pleased to share with you JHTV's annual report for Fiscal Year 2022. As we returned to the office last year and The Johns Hopkins University came back to life, we wanted to celebrate the vibrancy of the innovation environment on our campuses and our connection to the broader Baltimore startup ecosystem. As we see new technologies, new companies and new alumni launch from our Homewood and East Baltimore campuses, so, too, do we see the city continue to become a growing hub for innovation.

A5fb269c6d420a54 300x0 0 files Events Dhaval Patel headshot

LEIDEN, September 8, 2022 - MIMETAS, a global leader in organ-on-chip-based disease models for drug discovery and development, has appointed Dhaval Patel as Chair of its Board of Directors.

Dhaval Patel is Executive Vice President and Chief Scientific Officer at UCB, Belgium, clinical professor at the University of North Carolina Chapel Hill, and former Head of Research for the Novartis Institutes for BioMedical Research Europe.


BlueCloudTV Video

Just Funded selected the organizations listed in this article based on:

  • Track record
  • Executive leadership
  • Market share
  • Innovation
  • ESG rating

Shannon Wolfson from BlueCloudTV Interviews Dr. Harsha Rajasimha, Founder and CEO of Jeeva eClinical Cloud. The story behind the company and the vision to increase diversity in clinical trials.

Shuttle Pharmaceuticals 768x402

On its first day as a publicly traded company Wednesday, Rockville-based Shuttle Pharmaceuticals Holdings Inc. (NASDAQ: SHPH) saw its shares climb a staggering 373% to close at $38.48. At one point late Wednesday, its shares were trading at above $65 — up more than 700% from their opening price.

In after-hours trading Wednesday, the stock was down about 17% from its close and trading around $32 a share.

The eye-popping gains came on a day when all the major U.S. stock indexes fell.


BioTalk Shealy A

Brett Shealy, Executive Director of the Life Sciences Banking Team with J.P.Morgan, joins Rich Bendis on BioTalk to discuss his Career, BioHealth Investment, and the upcoming 2022 BioHealth Capital Region Forum/Investment Conference/Crab Trap.

Listen now via Apple, Google, Spotify, Amazon Podcasts, or TuneIn

Dr. Kurt Newman, president and CEO of Children's National Hospital, has spent 11 years in the role.

The first time Kurt Newman walked into the Children’s National Hospital atrium as a thirtysomething surgical fellow in 1984, he felt like he was home. He didn’t want to leave.

Nearly four decades later, Newman is announcing his retirement as the D.C. pediatric hospital’s president and CEO.

Image: Dr. Kurt Newman, president and CEO of Children's National Hospital, has spent 11 years in the role. EMAN MOHAMMED

Cursor and Equity Incubator Fall 22 Flyer

Thank you for your interest in joining the Entrepreneurship Lab Equity Incubator at the Universities at Shady Grove! We will be accepting teams and individuals. You may apply individually, although we recommend having at least one other team member.

For this program, we are inviting individuals who identify with a gender, racial/ethnic, or other identity which, historically has not been dominant in receiving entrepreneurship support. We do this because we aim to create a collaborative, diverse cohort of entrepreneurs that can contribute unique perspectives in a supportive environment as we foster new venture formation and growth.

Download the PDF

Click here to learn more.


Emergent Logo

GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection. Emergent and CEPI (the Coalition for Epidemic Preparedness Innovations) are co-funding this program.

“Over the last 24 years, Emergent’s mission to protect and enhance life and commitment to help mitigate public health threats have remained unchanged,” said Kelly Warfield, Ph.D., SVP for research and development at Emergent BioSolutions. “We are proud to deploy our product development and partnering capabilities to address emerging infectious diseases like Lassa fever, for which there is currently no approved vaccine or therapeutic, and to advance our pipeline for patients.”

  • The competition nurtures young scientists around the globe
  • QIAGEN-Verogen generously donated a combined instrument and reagents prize package worth up to $ 60,000
  • Three young forensic scientists have been recognized for work in human identification (HID) and forensics

Germantown, Maryland, and Hilden, Germany, September 5, 2022 -- QIAGEN today announced the winners of its second Young Investigator Awards (YIA). The winner and two runners-up were recognized for their outstanding scientific work using next-generation sequencing (NGS) in human identification (HID). The competition encourages and supports new generations of forensic scientists who show potential to make a lasting impact on human identity and forensics. The three finalists were honored during the International Society for Forensic Genetics (ISFG) Congress in Washington D.C.

The 2022 Young Investigator Award went to Maria Martin Agudo, a PhD candidate at the Department of Forensic Sciences (Forensic Genetics Research Group), Oslo University Hospital in Norway. Haley Omeasoo from The University of Montana, USA and Chiara Fantinato from the Department of Forensic Sciences, Oslo University Hospital, Norway, were the two runners-up. All three finalists received all-inclusive invitations to the International Society for Forensic Genetics (ISFG) Congress.

Ampel logo

GENOME WEB, CHICAGO, IL, September 1, 2022 - - After nine years in business, precision medicine company AMPEL BioSolutions is broadening its market from pharmaceutical companies to healthcare providers and their patients.

This summer, the firm had an early-access release of a series of gene expression tests coupled with analysis and clinical decision support, starting with LuGene®, a blood test for systemic lupus erythematosus, and DermaGene®, a skin biopsy test to differentiate between several dermatological conditions including psoriasis, scleroderma, and atopic dermatitis.